Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcg
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Mild Intermittent Asthma
Conditions
Mild Intermittent Asthma
Trial Timeline
Jul 1, 2008 → Dec 1, 2008
NCT ID
NCT00716963About Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcg
Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcg is a approved stage product being developed by AstraZeneca for Mild Intermittent Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT00716963. Target conditions include Mild Intermittent Asthma.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00716963 | Approved | Completed |
Competing Products
20 competing products in Mild Intermittent Asthma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Neurosteroid enantiomer | Oragenics | Phase 2 | 44 |
| Ranirestat + Placebo | Eisai | Phase 2/3 | 65 |
| Aricept (donepezil hydrochloride) + placebo | Eisai | Approved | 85 |
| Donepezil HCl | Eisai | Approved | 85 |
| Donanemab + Aducanumab | Eli Lilly | Phase 3 | 77 |
| PPAR alpha + Hydrochlorothiazide + Placebo | Eli Lilly | Phase 2 | 52 |
| Elagolix | AbbVie | Approved | 85 |
| AZD1446 + Placebo | AstraZeneca | Phase 2 | 52 |
| MEDI1814 for IV injection + MEDI1814 for Subcutaneous Injection + IV Placebo + Placebo for Subcutaneous Injection | AstraZeneca | Phase 1 | 33 |
| AZD5213 + AZD5213 + AZD5213 | AstraZeneca | Phase 2 | 52 |
| budesonide/formoterol (Symbicort) | AstraZeneca | Phase 3 | 77 |
| MK-8931 | Merck | Phase 1 | 33 |
| Montelukast to placebo + Placebo to montelukast | Merck | Pre-clinical | 23 |
| Verubecestat 12 mg (Parts 1 and 2) + Verubecestat 40 mg (Parts 1 and 2) | Merck | Phase 3 | 77 |
| Aliskiren + Hydrochlorothiazide + Amlodipine | Novartis | Approved | 85 |
| LCZ696 + Sildenafil | Novartis | Phase 2 | 52 |
| QCZ484 + Placebo | Novartis | Phase 1 | 33 |
| Rivastigmine Patch | Novartis | Approved | 85 |
| AFQ056 | Novartis | Phase 1 | 33 |
| Canakinumab | Novartis | Phase 2 | 52 |